Evidence review
Ozempic vs Wegovy: Same Drug, Two Different FDA Approvals
Ozempic and Wegovy are both semaglutide. What differs is the FDA-approved indication, the maximum dose, and a cardiovascular-risk claim only one carries.
On this page
The Desk's #1 pick
CoreAge Rx
AThe Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
Check availability- Semaglutide
- $149/mo
- Tirzepatide
- $349/mo
- Coverage
- All 50 states
- Access
- Compounded
Advertising disclosure · we may earn a commission at no extra cost to you. It never changes what we write about a product — an unflattering finding on a paying provider stays in.
Also on the board
Strut Health
B+The same molecule as a lozenge or an injection at the same price — the only place on this board where the needle is genuinely optional.
Check Strut Health availabilityOzempic and Wegovy are the same active ingredient, semaglutide, made by the same company, Novo Nordisk. The confusion is fair — nothing about the names tells you that. What actually separates them is the FDA paperwork: two different approvals, for two different purposes, at two different maximum doses.
Two approvals, four years apart
Ozempic was approved first, in December 2017, as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes — that is its only FDA-approved use. Wegovy followed in 2021, approved specifically for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition. Same molecule, filed twice, for two different jobs.
The dose ceiling is different
Ozempic's approved maintenance doses top out at 2 mg once weekly. Wegovy's go higher, to 2.4 mg once weekly — a meaningfully larger exposure at the top of the range, which is one reason a diabetes prescription is not a like-for-like substitute for a weight-management one even though the drug in the pen is identical.
Wegovy carries a claim Ozempic doesn't
In March 2024, the FDA approved a label expansion making Wegovy the first weight-management drug approved specifically to reduce the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and obesity or overweight1. That approval rests on the SELECT trial: 17,604 participants with existing cardiovascular disease and no diabetes, followed for a median of 3+ years, in which Wegovy reduced the composite rate of cardiovascular death, non-fatal heart attack or non-fatal stroke to 6.5% versus 8.0% on placebo2. Ozempic does not carry this indication — its own outcomes evidence is in diabetic populations, and in January 2025 the FDA separately approved Ozempic to reduce the risk of kidney disease progression and cardiovascular death specifically in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial34. The two drugs' outcomes claims are approved for different patient populations, and neither claim transfers to the other's label. Both trials, and what they mean beyond the weight-loss numbers, get the full sourced treatment in GLP-1, the heart and the kidneys.
What is actually identical
The molecule, the manufacturer, the general side-effect profile, and the boxed thyroid C-cell tumor warning are the same across both — see the full breakdown in GLP-1 side effects. Off-label prescribing of Ozempic for weight loss happens in practice, but it is prescribing outside the FDA-approved indication, at a lower dose ceiling than the drug purpose-approved for that job.
What this means for a telehealth prescription
A provider dispensing "semaglutide" through a compounding pharmacy is not selling either brand — see compounded vs brand-name GLP-1 for what that distinction actually changes. If brand-name access to either Ozempic or Wegovy specifically matters to you, filter for it on the best semaglutide providers board, where brand-filing rows are marked. And if the decision is really between the two molecules rather than the two brand names, semaglutide vs tirzepatide is the comparison that matters — or browse the full research library for the rest of the sourced evidence behind these drugs.
Frequently asked questions
Is Ozempic the same as Wegovy?
The active ingredient is identical — both are semaglutide, made by Novo Nordisk. What differs is the FDA-approved use: Ozempic for type 2 diabetes (approved 2017), Wegovy for chronic weight management (approved 2021), at a higher maximum dose than Ozempic.
Why does Wegovy have a higher dose than Ozempic?
Wegovy's approved maintenance dose goes up to 2.4 mg weekly; Ozempic tops out at 2 mg. The doses were set separately for each approved use based on the trials that supported each application.
Does Ozempic reduce cardiovascular risk the way Wegovy does?
Not on the same label claim. Wegovy's cardiovascular-risk-reduction indication, approved March 2024, is based on the SELECT trial in adults with obesity and existing cardiovascular disease. Ozempic's outcomes claim, approved January 2025, covers a different population — kidney disease and cardiovascular death risk reduction in adults with type 2 diabetes and chronic kidney disease, from the FLOW trial.
Can a doctor prescribe Ozempic for weight loss instead of Wegovy?
That happens in practice, but it is prescribing outside Ozempic's FDA-approved indication (type 2 diabetes), at a lower approved dose ceiling than Wegovy carries for weight management.
References
- U.S. Food and Drug Administration (2024). FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. FDA.gov, Press Announcements. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/37952131/
- Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/38785209/
- U.S. Food and Drug Administration (2025). Ozempic (semaglutide) injection — Supplemental Approval Letter, Chronic Kidney Disease Indication. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209637Orig1s025ltr.pdf
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Compounded vs Brand-Name GLP-1: How to Read the Trade-Off
Brand-name Wegovy and Zepbound are FDA-approved; compounded GLP-1 is not. Here is what that difference actually means for cost, access and safety.
ReadGLP-1 Dosage and Titration Schedules: Semaglutide and Tirzepatide
The FDA-approved dose-escalation steps for Wegovy and Zepbound, why the climb is slow by design, and what happens if you miss a week.
ReadHow to Inject GLP-1 Medications: Sites, Rotation and Timing
Where the FDA-approved instructions say to inject Wegovy or Zepbound, how to rotate sites correctly, and the timing rules for a weekly dose.
ReadIs Compounded GLP-1 Legit and Safe?
Compounded GLP-1 is legal but not FDA-approved. What 503A and 503B mean, why LegitScript verification matters, and how to vet a compounder before you buy.
ReadGLP-1 and Hair Loss: What Causes It, and When It Stops
Hair thinning is not on the Wegovy or Zepbound label, but it is widely reported and increasingly studied — the mechanism, timing and who is affected.
ReadGLP-1 Microdosing: What It Is, and What the Evidence Says
Microdosing GLP-1 means going below the FDA-approved starting dose, usually via compounded product. No randomized trial has tested it — what that gap means.
Read